Transplantation Updates

Just Released - Transplantation - November 2022 Issue

This month has a varied selection of ideas and discoveries of interest. COVID still ranks high in the clinical agenda and there are data on vaccine effectiveness and treatment strategies to help reduce the burden of disease. Monkey Pox raises some challenges for the field and some timely advice is provided here. Dysbiosis and the microbiome in alloimmunity is among the basic science papers catching the eye. Liver transplantation has a substantial set of papers of interest from across the world questioning some of the tenets of today on MELD and living liver exchange programs as well as the utility of Hep C in the KDPI. There are papers across the spectrum of clinical transplantation from kidney to heart, lung and islet to keep everyone reading as winter approaches.

Table of Contents

Around the World

Research Highlights

Game Changer

People in Transplantation

Expert Insight

Reviews


Transplantation - Week's Most Downloaded Paper

Anti-BAFF Therapy: A New Tool to Target B Cells in Antibody-mediated Rejection?

Maintaining long-term renal allograft survival remains a major challenge in kidney transplantation. Chronic active antibody-mediated rejection (AMR) accounts for the majority of late renal allograft failures. In AMR, B cells both generate donor-specific antibody (DSA) as well as present antigen, produce cytokines, and promote allograft injury. The efficacy of therapeutics commonly used to treat AMR demonstrate mixed results in clinical practice. Thus, clinicians and researchers have an interest to better understand the role of B cells in AMR and to identify effective targeted therapeutics.

Transplantation Direct - Highlighted Tweet

Understanding Local Hemodynamic Changes After Liver Transplant: Different Entities or Simply Different Sides to the Same Coin?

Liver transplantation is an extremely complex procedure performed in an extremely complex patient. With a successful technique and acceptable long-term survival, a new challenge arose: overcoming donor shortage. Thus, living donor liver transplant and other techniques were developed. Aiming for donor safety, many liver transplant units attempted to push the viable limits in terms of size, retrieving smaller and smaller grafts for adult recipients. With these smaller grafts came numerous problems, concepts, and definitions. The spotlight is now aimed at the mirage of hemodynamic changes derived from the recipients prior alterations. This article focuses on the numerous hemodynamic syndromes, their definitions, causes, and management and interconnection with each other. The aim is to aid the physician in their recognition and treatment to improve liver transplantation success.

TID COVID-19 Guideance - October 2022

The Transplant Infectious Disease Section (TID) has prepared a new update and guidance on the 2019 Novel Coronavirus (2019-nCov) for transplant ID clinicians.

TID 2022 Virtual - 14th International Transplant Infectious Disease Conference

Open to all Transplant Professionals!


Upcoming Webinars


In Case You Missed It - Recent Webinar Presentation


TTS-ILTS Paired Transplant Centers Program - Apply Today!

Program Schedule


Deadline to Apply: January 1, 2023
Program Start Date: April 1, 2023

WHO
An experienced supporting transplant center (SC) in the developed world is paired with an emerging transplant center (EC) to facilitate vital multidisciplinary training and an exchange of knowledge and expertise.
WHY
The project aims to benefit both centers. The SC is involvedin global health, and promotes ethical and competent transplantation in regions of the world with limited or no current access to transplantation. The EC connects with a multidisciplinary team of experts in transplantation from a world-leading center.
GOAL
The ultimate goal is for Level 3 centers to graduate and become true local centers of excellence for regional training and support.
STEPS
The TTS-ILTS Paired Transplant Centers Program is bound by a limited budget which it cannot exceed. This budget is divided over all center pairs who receive a different financial allocation dependent on their level within the program.
  • Level 1 - maximum annual allocation per pair: $ 3,500 USD
  • Level 2 - maximum annual allocation per pair: $12,000 USD
  • Level 3 - maximum annual allocation per pair: $15,000 USD
Programs Launched in April 2022
Dow Universtiy Hospital, Karachi, Pakistan paired with the University of Chicago, Chicago, USA

TTS and ILTS congratulates these teams and wishes them every success in their collaborations over the next six years and beyond.


TTS-RMEI Partnership CME Activity

This activity is intended for clinicians practicing in transplantation, infectious disease, and nephrology.

This activity is meant to improve clinician’s identification of resistant/refractory cytomegalovirus (CMV) and update them on newly approved treatment strategies for resistant/refractory CMV in solid organ transplant (SOT) patients.


DETAILS

CMV is one of the most common opportunistic infections affecting solid organ transplant recipients (SOTRs), conveying higher risks of complications, graft loss, morbidity, and mortality. Treatment options for CMV are limited, have similar mechanisms of action, suffer from cross-resistance, and have serious toxicities. Until recently, no treatment option was available in the resistant/refractory setting. This workshop, developed in collaboration with The Transplantation Society (TTS) and Dr. Camille Kotton, MD, FIDSA, FAST, will take you through a CMV primer and then move on to discuss cases submitted by your peers from transplant centers across the United States.

Upon completion of this activity, participants should be better able to:
  • Employ evidence-based antiviral treatment strategies for cytomegalovirus (CMV) in solid organ transplant (SOT) patients
  • Utilize antiviral resistance testing to identify SOT patients with treatment refractory or drug resistant CMV
  • Implement new treatment strategies in the management of resistant or refractory CMV in SOT patients

CME:

Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

Nurses - 0.75 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

Pharmacists - 0.75 Knowledge-based ACPE (0.075 CEUs)
  • CME / CE Released: 9/15/2022 Valid for credit through: 9/14/2023

https://www.medscape.org/viewarticle/979798



TTS Needs Assessment Survey - last chance to submit!

This survey focuses on issues encountered by physicians in day-to-day decision-making.

Your responses will aid TTS in developing strategies, programs and resources to improve access and transparency in transplantation, emphasizing increasing deceased donor organ transplantation.

The information collected will also aid the work TTS is doing as part of our World Health Organization collaboration.

All responses will be kept confidential and anonymous.

The survey will take 6+ minutes and must be done from a computer or tablet.

In the News 


Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada